# Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

> **NCT05404139** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 132 (estimated)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **OTHER:** Standard of Care SBRT and ADT

## Key facts

- **NCT ID:** NCT05404139
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-24
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2024-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05404139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05404139, "Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05404139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*